HUMA Latest Press Releases

-- October 28, 2026 --

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues Globe Newswire 8:00 AM

-- October 23, 2026 --

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner Globe Newswire 8:00 AM

-- October 15, 2026 --

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals Globe Newswire 8:00 AM

-- October 12, 2026 --

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 Globe Newswire 8:00 AM

-- September 28, 2026 --

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik Globe Newswire 8:00 AM

-- September 10, 2026 --

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 8:00 AM

-- September 9, 2026 --

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months Globe Newswire 8:00 AM

-- September 4, 2026 --

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA Business Wire 5:50 PM

-- August 24, 2026 --

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions Globe Newswire 8:00 AM

-- August 21, 2026 --

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA PRNewswire 10:00 PM

-- August 19, 2026 --

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results Globe Newswire 8:00 AM

-- August 18, 2026 --

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess Implantation; Cites Bioengineered Blood Vessel as 'Revolutionary Advancement' Globe Newswire 8:00 AM

-- August 12, 2026 --

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 7:00 AM

-- August 10, 2026 --

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA Business Wire 12:27 PM

-- August 7, 2026 --

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 Globe Newswire 8:00 AM

-- July 27, 2026 --

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting Globe Newswire 8:00 AM

-- July 14, 2026 --

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access Globe Newswire 8:00 AM

-- June 15, 2026 --

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting Globe Newswire 8:00 AM

-- June 10, 2026 --

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock Globe Newswire 9:08 PM

Humacyte, Inc. Announces Proposed Public Offering of Common Stock Globe Newswire 4:04 PM

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients Globe Newswire 4:01 PM

-- June 5, 2026 --

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewswire 3:52 PM

Market Data Delayed 15 Minutes